Updates are available Correction dated 2018-03-17
Click to view Correction: https://doi.org/10.1007/s13555-018-0234-5
-
Authors
Spindeldreher, Sebastian
Maillère, Bernard
Correia, Evelyne
Tenon, Maxime
Karle, Anette
Jarvis, Philip
Kolbinger, Frank
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals AG
- License Information
-
More Information
Article History
Received: 30 November 2017
First Online: 1 February 2018
Change Date: 17 March 2018
Change Type: Correction
Change Details: In the original publication, information regarding “ustekinumab” was incorrectly published under the Methods section. The correct information in the section “Antibodies and Control Protein” should be “(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)”. Infliximab, which is mentioned in that section, was not used in the study.
